Global Pulse Perspectives

.China’s Duplicity Biotherapeutics has actually submitted (PDF) paperwork for a Hong Kong IPO, finding a hidden sum to power a broad pipeline of antibody-drug conjugates

.Though Alkeus Pharmaceuticals’ dental eye disease asset fell short to substantially minimize geographic degeneration (GA) lesion growth, the biotech is presenting “medically meaningful” end results

.While the biotech investment scene in Europe has slowed quite adhering to a COVID-19 financing boom in 2021, a brand-new document from PitchBook proposes venture

.Merck &amp Co. has actually quickly made back a number of the costs of its Weapon Rehabs purchase, attracting $170 million beforehand by integrating the

.Cullinan Therapy was actually thrilled enough along with Harbour BioMed’s bispecific immune system reactor that it handed over $25 million in 2015 for the medicine’s

.Accept to this week’s Chutes &amp Ladders, our roundup of substantial management hirings, shootings and retirings across the field. Please send out the praise– or

.Compass Pathways’ journey to period 3 experimental anxiety information is taking longer than expected. Along with the trials overrunning through months, the biotech is letting

.Tip has actually mentioned period 3 records on its own near-approval ache medicine applicant suzetrigine, shedding light on just how the non-opioid painkiller mixes along

.Cognition Therapies’ phase 2 luster trial has actually taken a number of the luster off the Alzheimer’s illness medication candidate CT1812. The oral sigma-2 villain

.Invite to recently’s Chutes &amp Ladders, our roundup of considerable leadership hirings, firings and retirings around the business. Please deliver the compliment– or even the